Preclinical studies using siRNA or shRNA targeting MMP-2 or MMP-9 have shown that reducing these MMPs’ expression diminishes glioma cell invasion and enhances the response to chemotherapeutic agents [137,138]. The gene discussed is MMP2; the disease is central nervous system cancer.